Since 2013, Dr. Brantley has developed expertise in clinical and non-clinical pharmacology, pharmacokinetics, pharmacometrics and scientific writing. Dr. Brantley’s focus is mostly in early phase oncology and antiviral programs. Dr. Brantley has worked on approximately 6 approved drugs, 3 NDAs, 5 INDs, 60+ PK and population PK analyses.
Education